Achieved the critical milestone of positive operating cash flow in Q4 2025, validating the strategic thesis of the Greenbrook acquisition through revenue growth and expense discipline. Delivered 23% adjusted pro forma revenue growth driven by record capital shipments and a 28% increase in clinic revenue, reflecting successful integration of the national care delivery network. Realigned the NeuroStar capital sales team to focus on 'TMS-ready' accounts—practices with existing staff and insurance credent ...